Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: HOPE has shown to optimize graft liver preservation. However, the most used perfusion solutions as such as Belzer-MPS and its generics were initially for kidney purposes and given its composition, may not be the most suitable for the liver. The aim of this study is to compared Belzer-MPS generic (Perf-gen) with an IGL-2 solution (a modified IGL-1 solution enriched with increased PEG35 and glutathione contents) for HOPE purposes.
*Methods: Livers from Sprague Dawley rats were extracted and preserved either in IGL-2 or PerfGen solution (7 hours; 4ºC), followed by HOPE (1 hour at 4 ºC) and then normothermic reperfusion (1 hour at 37ºC). After organ recovery, liver injury mitochondrial damage (GLDH) and Aldehyde Dehydrogenase-2 (ALDH2) activity were measured.
*Results: Liver injury (measured as ATL/AST) and mitochondrial damage (measured as GLDH) levels, shows a significant decrease during HOPE phase. Mitochondrial ALDH2 activity is enhanced in the IGL-2 group when compared to Perf-gen.
*Conclusions: IGL-2 perfusate improved liver graft preservation when compared with Perf-gen during HOPE through mitochondrial protection.
To cite this abstract in AMA style:Panisello-Rosello A, Castro-Benítez C, Folch-Puy E, Rosello-Catafau J, Adam R. New IGL-2 Perfusate in Liver HOPE Strategies [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/new-igl-2-perfusate-in-liver-hope-strategies/. Accessed October 23, 2020.
« Back to 2020 American Transplant Congress